Modular Medical Inc. has announced a significant milestone with the first human use of its MODD1 insulin pump, receiving approval under the institutional review board from the United States Food and Drug Administration (FDA). The company plans to expand the deployment of MODD1 to a larger number of clinicians by mid-August, marking a critical step in advancing its user-friendly and affordable insulin delivery solution. Modular Medical aims to target the $3 billion adult "almost-pumpers" market with this innovative technology. Further updates on this development are anticipated as the company progresses with its clinical trials.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。